SCHEMBL1102495

SCHEMBL1102495

c1ccc(-c2ccc3ccccc3c2-c2c3ccccc3c(-c3c(-c4ccccc4)ccc4ccccc34)c3cnccc23)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 2/20 0.57
MAPT P10636 5/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
HPGD P15428 3/20 0.43
MAPK10 P53779 1/20 0.42
CYP11B1 P15538 4/20 0.41
GPR84 Q9NQS5 1/20 0.40
LMNA P02545 2/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP17A1 P05093 3/20 0.38
CYP11B2 P19099 3/20 0.38
CYP3A4 P08684 2/20 0.38
HASPIN Q8TF76 1/20 0.38
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102603 0.97 TNF (0.54) TNFMAPTKDM4EALDH1A1HPGD
SCHEMBL1102809 0.93 TNF (0.57) TNFMAPTKDM4EALDH1A1HPGD
SCHEMBL1102839 0.91 TNF (0.48) TNFMAPTKDM4EALDH1A1HPGD
SCHEMBL1102879 0.83 TNF (0.69) TNFMAPTKDM4EALDH1A1HPGD
SCHEMBL1102708 0.82 TNF (0.56) TNFKDM4EALDH1A1HPGDCYP11B1
SCHEMBL17442108 0.81 ALDH1A1 (0.50) TNFMAPTKDM4EALDH1A1HPGD
SCHEMBL31603915 0.81 ALDH1A1 (0.50) TNFMAPTKDM4EALDH1A1HPGD
SCHEMBL1102751 0.80 TNF (0.54) TNFKDM4EALDH1A1HPGDCYP11B1
SCHEMBL1102849 0.80 TNF (0.69) TNFMAPTKDM4EALDH1A1HPGD
SCHEMBL1102652 0.80 TNF (0.59) TNFMAPTKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 TNF 3803/4885MAPT 3162/4885KDM4E 3367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.